The synthesis of a series of neoglycolipid conjugates of foscarnet as potential drug targeting forms or lipophilic prodrugs of foscarnet is described. The compounds were obtained from suitably protected neoglycolipids, in which the lipid chain consisted of 12 to 20 carbon atoms, by ethoxycarbonylphosphonylation at the 6-hydroxyl or 4-hydroxyl group followed by deprotection. 
Foscarnet is approved for the treatment of HCMV retinitis as well as acyclovir-unresponsive HSV in AIDS patients. However, foscarnet is poorly absorbed orally and is usually administered as an intermittent infusion at 8 to 12 h intervals (Aweeka et al., 1989; Taburet et al., 1992; Noormohamed et al., 1998) . Owing to its highly ionic nature, foscarnet shows poor penetration into cells and has to be administered in high doses (200 mg/kg/day) in order to achieve a therapeutic effect (Wagstaff & Bryson, 1994) . Moreover, dose-related toxicity is significant on treatment with foscarnet (Chrisp & Clissold, 1991) . Thus a drug-targeting form of foscarnet with enhanced antiviral activity, improved transport properties and decreased toxicity would be of significant benefit.
In previous studies, alkyl, aryl, acyloxymethyl, 4-acyloxybenzyl and S-acylthioethyl mono-, di-and triesters of foscarnet have been prepared as potential bioreversible prodrugs (Norén et al., 1983; Iyer et al., 1989 Iyer et al., , 1994 Briggs et al., 1996 Briggs et al., , 1997 Meier et al., 1998) . It has previously been shown that triesters of foscarnet are not suitable as prodrugs owing to their instability towards chemical hydrolysis at physiological pH and their propensity to undergo primarily P-C bond scission (Krol et al., 1991; Mitchell et al., 1991 Mitchell et al., , 1992 Krol & Thatcher, 1993) . Although P,Cdiesters of foscarnet were more suitable as prodrugs, the best of these esters, the P,C-dipivaloyloxymethyl ester, gave Introduction an oral bioavailability of foscarnet of approximately 25% following administration to rats, which is no greater than that obtained with oral foscarnet itself (Briggs et al., 1996) .
Another approach has been that of Hostetler and coworkers who have synthesized a number of lipophilic derivatives of foscarnet with enhanced antiviral activity in virus-infected cells. These derivatives include glycerolipid conjugates (Hostetler et al., 1996) , alkoxypropyl conjugates (Kini et al., 1997a) , 2-O-alkylglycerolipid conjugates (Kini et al., 1997b) and alkylthioglycerol conjugates (Beadle et al., 1998) of foscarnet. By using radiolabelled compounds, it was shown that the glycerolipid conjugate, 1-O-octadecyl-sn-glycero-3-phosphonoformate, is taken up more extensively into cells than foscarnet and that the conjugate was converted by intracellular enzymes to foscarnet, the active antiviral agent (Hostetler et al., 1996) .
In this paper, we report the synthesis and antiviral evaluation of a series of neoglycolipid conjugates of foscarnet [6a-g and 12, (Figure 1 )]. A neoglycolipid is a glycolipid that is usually absent or present in very small quantity in normal cells or tissues (Hakomori et al., 1982) . It was reasoned that these neoglycolipid conjugates, like the glycerolipid conjugates, should be enzymatically cleaved intracellularly following uptake into cells with the release of foscarnet, thus acting as drug targeting forms or lipophilic prodrugs of foscarnet. The effect of lipid chain length on the antiviral activity and cytotoxicity of the neoglycolipid conjugates of foscarnet in human foetal lung cells infected with HCMV and HSV-1 has been investigated. In the synthesized neoglycolipid conjugates, the carboxyphosphonyl substituent was attached to the 6-hydroxyl group, or in one case (12), to the 4-hydroxyl group, of the neoglycolipid moiety, which had either the α-or the β-anomeric configuration. Except for the neogalactolipid conjugate 6d, the compounds were neoglucolipid conjugates. General procedure for the preparation of the protected glycosides
Materials and Methods: Chemistry
To a solution under argon of the glycosyl donor (mixture of anomeric acetates) (5 mmol) and the alcohol (1.5 equivalent) in CH 2 Cl 2 /Et 2 O (1/2, 40 ml) or CH 2 Cl 2 (40 ml), was added activated 4Å crushed molecular sieves. The mixture was stirred for 20 min, cooled to 0°C in an ice/water bath and trimethylsilyl triflate (TMSOTf ) (1.05 equivalent) was added. The reaction was kept for 30 min at 0°C, and then allowed to warm up to room temperature.
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Figure 1. Structures of foscarnet and its neoglycolipid conjugates 6a-g and 12
After 3 h the reaction mixture was neutralized by addition of triethylamine (1.2 equivalent) diluted with CH 2 Cl 2 (40 ml), filtered and evaporated. FC of the residue gave the glycoside.
n-Octadecyl 2, 3,4,6-tetra-O-benzyl-α-D-glucopyranoside (1a) . Acetyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside (3.24 g, 5.56 mmol) and n-octadecanol gave after FC (eluent 1: 1/11) 3.097 g of 1a (71% 1, 80.1, 77.8, 75.6, 75.0, 73.4, 73.1, 70.1, 68.5, 68.2, 31.8-14 .0 (C alkyl).
Cis-9-octadecen-1-yl 2, 3,4,6-tetra-O-benzyl-α-D-glucopyranoside (1b) . Acetyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside (4 g, 6.865 mmol) and cis-9-octadecen-1-ol gave after FC (three times, eluent 1: 1/11) 3.719 g of 1b (68%). R f =0.33 (eluent 1: 1/8 1, 80.1, 77.7, 75.6, 75.0, 73.4, 73.0, 70.0, 68.5, 68.2, 31.8-14 .1 (C alkyl).
Trans-9-octadecen-1-yl 2, 3,4,6-tetra-O-benzyl-α-D-glucopyranoside (1c) . Acetyl 2,3,4,6-tetra-O-benzyl-D-glucopyranoside (4 g, 6.865 mmol) and trans-9-octadecen-1-ol gave after FC (eluent 1: 1/11) 3.3 g of 1c (61%). R f =0.30 (eluent 1: 1/10).
1 H-NMR (CDCl 3 ): δ 7. 36-7.12 (m, 20H-arom.), 5.39-5.37 (m, 2H), 4.99 (d, J=11.0), 4.84-4.44 (m, 8H), 4.00 (t, J=9.2), 3.80-3.59 (m, 5H), 3.56 [dd, J=9.6, 3.6 , H-C(2)], 3.42 (dt, J=9.7, 6.7), 1.98-1.94 (m, 4H), 1.64-1.59 (m, 2H), 1.35-1.26 (m, 22H), 0.88 (t, J=6.8, 3H).
13 C-NMR (CDCl 3 ): δ 138.9-137.9 (4C arom.), 130.3-127.4 (C arom., 2C olef.), 96.8 [C(1)], 82.0, 80.1, 77.7, 75.5, 74.9, 73.4, 73.0, 70.0, 68.5, 68.1, 3, 4, 2, 3, 4, 8.967 mmol) and eicosanol gave after 15 h, work up and FC (eluent 1: 1/4) 1.45 g of 1d (26%). R f =0.24 (eluent 1: 1/4 70.9, 70.5, 70.2, 68.9, 67.0, 61.2, 31.9-14 .0 (C alkyl and acetyl).
General procedure for preparation of the deprotected glycosides Benzyl ethers were deprotected either by hydrogenolysis with palladium on charcoal (McCloskey, 1957) , or by Birch reduction (Philips et al., 1973) . O-Acetyl groups were removed by basic hydrolysis (Conchie & Levvy, 1963) .
A suspension of 1a (1.28 g, 1.615 mmol) and 10% Pd/C (250 mg) in AcOEt/EtOH (1/1, 30 ml) was shaken for 3 h under an atmosphere of 300 kPa to give 2a. The reaction mixture was filtered, and washed twice with 40 ml of eluent 3 (7/2/1). The combined filtrates were evaporated and the residue was dried (high vacuum). The product (594 mg, 85%) was directly used in the next reaction step without further purification. R f =0.19 (eluent 2: 5/1).
Cis-9-octadecen-1-yl-α-D-glucopyranoside (2b). A solution of 1b (2.184 g, 2.76 mmol) in THF (15 ml) was added dropwise over a period of 30 min to a solution of sodium (1.01 g, 43.9 mmol) in liquid ammonia (200 ml). The mixture was left stirring at -35°C. After 5 h, MeOH (20 ml) and NH 4 Cl (2.34 g) were added and the reaction mixture was left to warm up to room temperature. The ammonia was removed by a continuous current of air applied overnight. The solid residue was suspended in eluent 2 (3/1, 100 ml) and filtered. Concentration of the filtrate, followed by FC (eluent 2: 10/1) gave 2b (642 mg, 54 %). R f =0.23 (eluent 2: 10/1 Trans-9-octadecen-1-yl-α-D-glucopyranoside (2c). A solution of 1c (2.4 g, 3.03 mmol) in THF (15 ml) was added dropwise over a period of 30 min to a solution of 1.4 g of sodium (60 mmol) in 200 ml of liquid ammonia. The mixture was left stirring at -35°C. After 5 h, MeOH (20 ml) and NH 4 Cl (3.21 g) were added and the reaction mixture was left to warm up to room temperature. The ammonia was removed by a continuous current of air applied Anti-HSV-1 and HCMV activity of neoglycolipid foscarnet conjugates overnight. The solid residue was suspended in eluent 2 (3/1, 100 ml) and filtered. Concentration of the filtrate, followed by FC (eluent 2: 10/1) gave 728 mg of 2c (56% 73.6, 71.8, 71.3, 69.9, 69.1, 67.8, 61.1, 32.1-13.4 (C alkyl) . -β-D-galactopyranoside (2d) . To a solution of 1d (1.38 g, 2.194 mmol) in MeOH (50 ml) was added a solution of MeO -Na + in MeOH (0.01 M, 20 ml). After 3 h the reaction mixture was neutralized by addition of cation exchanger resin [Dowex 50W-X8 (H) standard grade, particle size 0.39-1.00 mm] and diluted with CHCl 3 (100 ml). Filtration and evaporation gave 990 mg of 2d (98 %), which was directly used in the next reaction step without further purification. R f =0.21 (eluent 2: 5/1).
Eicosyl
General procedure for the preparation of the 2,3,4-tri-O-benzoyl-6-O-trityl-substituted glycosides A solution of the glycoside (3 mmol), triphenylmethyl chloride (1.1 equivalent) and a catalytic amount of 4-dimethylaminopyridine (DMAP) in 120 ml of pyridine was stirred overnight (14 h) at 70°C. The solution was brought to room temperature, diluted with 60 ml of CH 2 Cl 2 and benzoyl chloride (8 equivalent) was added. After 12 h the reaction mixture was diluted with CH 2 Cl 2 (60 ml) and washed with a saturated solution of NaHCO 3 , then with H 2 O and finally dried over MgSO 4 . Filtration and evaporation (rotavapor, co-evaporation of the traces of pyridine with toluene) followed by FC gave the title compounds.
n-Octadecyl 2, 3,4-tri-O-benzoyl-6-O-trityl-α-D-glucopyranoside (3a) . 2a (660 mg, 1.37 mmol) gave after FC (eluent 1: 1/8) 965 mg of 3a (72%). R f =0.25 (eluent 1: 1/8). Cis-9-octadecen-1-yl 2, 3, . 2b (642 mg, 1.5 mmol) gave after FC (eluent 1: 1/9) 1.148 mg of 3b (78%). R f =0.23 (eluent 1: 1/9 86.6, 72.3, 71.0, 69.7, 69.3, 68.4, 62.6, 31.8-14 .0 (C alkyl).
Trans-9-octadecen-1-yl 2, 3,4-tri-O-benzoyl-6-O-trityl-α-D-glucopyranoside (3c) . 2c (728 mg, 1.69 mmol) gave after FC (eluent 1: 1/9) 1.590 mg of 3c (95%). R f =0.23 (eluent 1: 1/9). (1)], 86.6, 72.3, 71.0, 69.7, 69.3, 68.4, 62.6, 32.6-14 .1 (C alkyl).
Eicosyl 2,3,4-tri-O-benzoyl-6-O-trityl-β-D-galactopyranoside (3d)
. 2d (990 mg, 2.15 mmol) gave after FC (gradient eluent 1: 1/12 to 1/8) 1.98 g of 3d (84%). R f =0.19 (eluent 1: 1/10). 86.9, 72.5, 71.9, 70.3, 70.0, 68.1, 61.0, 31.9-14 .1 (C alkyl).
n-Dodecyl 2,3,4-tri-O-benzoyl-6-O-trityl-α-D-glucopyranoside (3e). n-Dodecyl-α-D-glucopyranoside
(1 g, 3.52 mmol) gave after FC (eluent 1: 1/8) 2.52 g of 3e (79 %). R f =0.21 (eluent 1: 1/9). 86.6, 72.3, 71.0, 69.7, 69.3, 68.4, 62.6, 31.9-14 .1 (C alkyl).
General procedure for the preparation of the 2,3,4-tri-O-benzoyl-substituted glycosides To a solution of the trityl derivative (2 mmol) in CHCl 3 /MeOH (2/1, 90 ml) was added para-toluenesulphonic acid monohydrate to pH 1-2. After 3 h the solution was diluted with 50 ml of CH 2 Cl 2 , washed with a saturated solution of NaHCO 3 , then with H 2 O and finally dried over MgSO 4 . Filtration and evaporation followed by FC gave the title compounds. 72.0, 70.3, 69.8, 69.6, 68.7, 61.0, 31.8-14 .1 (C alkyl).
Cis-9-octadecen-1-yl 2, 3,4-tri-O-benzoyl-α-D-glucopyranoside (4b) . 3b (1.08 g, 1.1 mmol) gave after FC (eluent 1: 1/3.5) 590 mg of 4b (72%). R f =0.23 (eluent 1: 1/3.5). 
Eicosyl 2,3,4-tri-O-benzoyl-β-D-galactopyranoside (4d).
3d (1.5 g, 1.48 mmol) gave after FC (eluent 1: 1/3) 901 mg of 4d (79%). R f =0.24 (eluent 1: 1/3). 72.0, 70.3, 69.8, 69.6, 68.7, 61.0, 31.8-14 .0 (C alkyl). (Tickle et al., 1998) (0.34 g, 0.89 mmol) was treated according to the general procedure for the preparation of the 2,3,4-tri-O-benzoyl-6-O-trityl-substituted glycosides to give n-tetradecyl
Detritylation of n-tetradecyl 2,3,4-tri-O-benzoyl-6-Otrityl-α-D-glucopyranoside was performed according to the general procedure, with stirring for 1 h only, to give after FC (eluent 1: 1/3.5) 300 mg of 4f (48%). 70.5, 69.9, 69.6, 68.7, 61.1, 31.9-14 .1 (C alkyl). (Tickle et al., 1998) (0.084 g, 0.22 mmol) was treated according to the general procedure for the preparation of the 2,3,4-tri-O-benzoyl-6-O-trityl-substituted glycosides above to give n-tetradecyl
n-Tetradecyl 2,3,4-tri-O-benzoyl-β-D-glucopyranoside (4g). n-Tetradecyl-β-D-glucopyranoside
Detritylation of n-tetradecyl 2,3,4-tri-O-benzoyl-6-Otrityl-β-D-glucopyranoside was performed, according to the general procedure, with stirring for 1 h only, to give after FC (eluent 1: 1/3.5) 56 mg of 4g (36%). 74.6, 73.0, 71.9, 70.3, 69.7, 61.4, 31.9-14 .1 (C alkyl).
General procedure for the preparation of the protected neoglycolipid conjugates of foscarnet A solution of the hydroxy-compound (1 mmol) in dry CH 2 Cl 2 (20 ml) was added dropwise to an ice cold solution of ethoxycarbonylphosphonic dichloride (1.6 mmol) in dry CH 2 Cl 2 (15 ml). The reaction mixture was stirred at 0°C for 1 h, and then for 3 h at room temperature. The solvent was removed under reduced pressure. The residue was dried in high vacuum for 5 min and re-dissolved in AcOEt (20 ml). After addition of H 2 O (20 ml), the two phases were vigorously stirred for 10 min (emulsion). The organic phase was separated and washed with H 2 O. The aqueous phases were extracted twice with AcOEt (5% of MeOH was added when the phase separation was difficult). The combined organic phases were dried (MgSO 4 ), and evaporated. FC of the residue gave the title compounds. 3, . 4d (854 mg, 1.1 mmol) gave after FC (eluent 4) 803 mg of 5d (80%). R f =0.25 (eluent 2: 5/1). 
n-Tetradecyl 6-O-ethoxycarbonylphosphonyl-2,3,4-tri-
O-benzoyl-α-D-glucopyranoside (5f). Deviation from the general procedure: stirring at room temperature for only an extra 1 h, and after extraction drying with Na 2 SO 4 . 4f (1 g, 1.45 mmol) gave after FC (eluent 3: 10/1.5/0.5) 413 mg of 5f (34%). R f =0.25 (eluent 3: 10/1.5/0.5). General procedure for the preparation of the neoglycolipid conjugates of foscarnet
The protected neoglycolipid conjugate of foscarnet (1 mmol) was suspended in H 2 O (25 ml) at room temperature. A 0.4 M solution of NaOH (25 ml) was added [insoluble product that stuck to the walls of the flask was washed down with THF (10 ml)]. The suspension was left for 3 h at room temperature, brought to pH 5-5.3 by addition of cation exchange resin [Dowex 50W-X8 (H) standard grade, particle size 0.39-1.00 mm], filtered and the solvent was removed under reduced pressure (1.3 kPa, 30°C). If the solution could not be concentrated by drying in a rotavapor (owing to rapid formation of a foam), the THF was removed by a continuous current of air overnight. The residue was purified by RP (eluent 5). The fractions containing the monoester were collected and the MeOH was evaporated (rotavapor, 20°C). Lyophilization gave the title compounds.
Disodium n-octadecyl 6-O-carboxyphosphonyl-α-Dglucopyranoside (6a)
. 5a (500 mg, 0.568 mmol) gave after RP (eluent 5) 190 mg of 6a (57%). R f =0.06 (eluent 3: 7/2/1). 
Disodium cis-9-octadecen-1-yl 6-O-carboxyphosphonyl-α-D-glucopyranoside (6b)
. 5b (500 mg, 0.569 mmol) gave after RP (eluent 5) 176 mg of 6b (53%). R f =0.06 (eluent 3: 7/2/1). 
Disodium eicosyl 6-O-carboxyphosphonyl-β-D-galactopyranoside (6d)
.
Disodium n-dodecyl 6-O-carboxyphosphonyl-α-D-glucopyranoside (6e
Dodecyl 4,6-O-benzylidene-β-D-glucopyranoside (7).
Dodecyl β-D-glucopyranoside (1.5 g, 4.3 mmol) was dissolved in a mixture of benzaldehyde and formic acid (1/1, 14 ml 80.4, 74.3, 72.9, 70.4, 68.5, 66.1, 31.8-14 .0 (C alkyl).
Dodecyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-glucopyranoside (8).
An 80% dispersion of NaH (213 mg, 7.085 mmol) in mineral oil was added to a stirred solution of 7 (1.289 g, 2.952 mmol) in dry DMF (30 ml). After 10 min benzyl bromide (775 µl, 6.5 mmol) was added and the reaction was stirred overnight. MeOH (10 ml) was added and after 20 min the reaction mixture was diluted with Et 2 O (80 ml) and extracted with a saturated solution of NaHCO 3 , then with H 2 O and finally dried over Na 2 SO 4 . Filtration and evaporation gave a residue which after FC (eluent 1:1/14) yielded 1.67 g of 8 (92 %). R f =0.24 (eluent 1:1/14). 81.5, 80.9, 75.3, 70.5, 68.8, 66.0, 3, . NaCNBH 3 (849 mg, 13.5 mmol) was added to an ice-cold solution of 8 (1.67 g, 2.7 mmol) in THF (50 ml). After 10 min at 0°C the solution was acidified to pH 3 by slow addition of a saturated solution of HCl in Et 2 O. The reaction mixture was left to warm up to room temperature, and left stirring for 3 h. After dilution with AcOEt (100 ml), washing with a saturated solution of NaHCO 3 and with a saturated solution of NaCl and drying (MgSO 4 ), the organic phase was evaporated. The residue yielded after FC (eluent 1: 1/5) 1 g of 9 (60%) together with 474 mg of recovered 8 (28%). R f =0.19 (eluent 1: 1/5). 81.6, 75.1, 74.5, 74.1, 73.5, 71.4, 70.2, 70.0, 31.8-14 .0 (C alkyl). 
Dodecyl 4-O-ethoxycarbonylphosphonyl 2,3,6-tri-Obenzyl-β-D-glucopyranoside (10)
Dodecyl 4-O-ethoxycarbonylphosphonyl-β-D-glucopyranoside (11).
A suspension of 10 (950 mg, 1.258 mmol) and 10% Pd/C (300 mg) in AcOEt/EtOH (1/1, 30 ml) was shaken for 3 h under an atmosphere of 300 kPa. The reaction mixture was filtered through a pad of celite, which was again washed four times with 40 ml of eluent 3 (7/2/1). The combined filtrates were evaporated, dried and gave after FC (eluent 3 gradient: 8/1.5/0.5 to 7/2/1) 415 mg of 11 (68%). R f =0.19 (eluent 3: 8/1.5/0.5). 
Disodium dodecyl 4-O-carboxyphosphonyl-β-D-glucopyranoside (12)
. 11 (335 mg, 0.691 mmol) gave after RP (eluent 5) 301 mg of 12 (87 %). R f =0.13 (eluent 3: 7/2/1). 
Materials and Methods: Virology
HCMV and HSV-1 antiviral assays Cell culture. Human foetal lung fibroblasts (HL, obtained from the Department of Virology, Sahlgrenska Hospital, Gothenburg, Sweden) were cultured in medium consisting of Eagle's MEM (Gibco) supplemented with 2 mM L-glutamine, 2% foetal calf serum (FCS, Bodinco, Holland), 10000 IU/l of penicillin and 10 mg/l of streptomycin. Maintenance medium consisted of Dulbecco's modified medium (DMEM), supplemented with 2 mM L-glutamine, 10% FCS and penicillin and streptomycin.
Virus strains. HCMV Towne (VR 977, ATCC) and a laboratory strain of HSV-1 (R39) were used for the evaluation. The strains had been stored at -70 O C and fresh aliquots were used in each experiment.
ELISA. Primary human lung fibroblasts (90×10
3 cells/well) were incubated in 96-well plates at 37°C in 5% CO 2 for 3 to 5 days until confluent, whereupon virus and antiviral compounds were added. The configuration of the microtitre plates comprised eight uninfected control wells, one virusinfected control well per virus dilution and five virus dilutions to which 11 concentrations of antiviral compounds in twofold dilutions were added. After removal of the growth medium, 200 µl of DMEM was added to the uninfected control wells and 200 µl virus inoculum was added to the remaining wells. The plates were incubated for 60 min at 37°C to facilitate virus adsorption. The fluid was aspirated from each well and 200 µl of fresh medium was added to the uninfected control wells and virus dilution control wells. Increasing concentrations of the antiviral compounds diluted in DMEM were added to the remaining wells. The plates were then incubated at 37°C in a humidified atmosphere of 5% CO 2 for 2 days (HSV-1) or 7 days (HCMV). The CPE was estimated microscopically and the concentration of the test compound that gave rise to signs of cytotoxicity, defined as when the colour of the maintenance medium remained unchanged and the cells shrivelled, was noted.
The ELISA procedure for the HCMV antiviral assay is described elsewhere (Ljungdahl-Ståhle et al., 1998) .
For the ELISA procedure of HSV-1, 20 µl of 5% Triton-X 100 were added to each well and the plates were frozen and thawed to disrupt the cells. Then 100 µl was transferred to a corresponding plate coated with guinea pig immunoglobulin (Ig) G antibodies directed against HSV-1 and allowed to incubate for 2 h at 37°C. 100 µl of a second antibody [rabbit antibodies, B114, directed against HSV-1 (Daco)] diluted in ELISA buffer (PBS with 0.5% BSA, 0.05% Tween 20 and 10% FCS) were added to each well and incubated for 60 min at 37°C. The wells were washed five times and 100 µl affinity-purified swine antirabbit IgG (Orion Diagnostica) conjugated to alkaline phosphatase and diluted in ELISA buffer were added. After incubation for 60 min at 37°C, the wells were washed five times. 100 µl of substrate [p-nitrophenyl phosphate (Sigma)] at 1 mg/ml in diethanolamine buffer pH 9.8, containing 0.5 M magnesium chloride, were added to each well and the colour reaction was developed at room temperature. The reaction was stopped after 30 min by adding 100 µl 1 M sodium hydroxide to each well. The absorbance was measured at 405 nm and at a reference wavelength of 650 nm using an E-max spectrophotometer (Molecular Devices, Calif., USA). The concentration of antiviral substance giving a 50% inhibition of viral growth (IC 50 ) after correction for the background absorption was calculated.
Cytotoxicity tests
The cytotoxicity of the compounds in human foetal lung cells was assessed using the MTT tetrazolium salt assay. The cells were seeded 6 days before the experiment and grown to confluency in 24-well plates. On the day of the experiment, compounds were dissolved to final concentrations (1 µM-3 mM) in incubator-equilibrated growth medium and added to the cells for 48 h. The experiment was carried out in duplicate, samples being taken in triplicate. Normally, mitochondrial enzymes have the capacity to transform MTT tetrazolium salt into MTT formazan, a coloured product that can be measured spectrophotometrically (Mossman, 1983) . In brief, MTT tetrazolium salt was dissolved in serum-free culture medium at a concentration of 0.3 mg/ml and then added to the cells for 1 h at the end of the exposure time. After 1 h, the medium was aspirated, isopropanol was added and aliquots were transferred to a 96-well plate. The absorbance was measured at 592 nm. Results were expressed as the percentage of intact cells compared to control. Besides assessing cytotoxicity, the MTT assay also provides an indication of mitochondrial metabolic function.
Materials and Methods: In Vitro and In vivo Hydrolysis
In vitro hydrolysis in tissue homogenates
By means of a previously established procedure (Briggs et al., 1997) , in vitro hydrolysis experiments were performed with compound 6f using rat liver or intestine homogenates. After incubation at 37°C, samples (0.5 ml) were withdrawn immediately after addition of test compound and after 5, 15, 60 and 240 min and diluted with 0.5 ml methanol. After centrifuging, the presence of phosphonoformate in the resulting samples was monitored by an HPLC method (Pettersson et al., 1989) . In vivo experiments in rats According to a previously described procedure (Briggs et al., 1997) , compound 6f was administered in aqueous solution orally to a rat (dose 180 µmol/kg). Blood samples were collected at the following times after administration: 15 and 30 min, 1, 1.5, 2, 4, 6 and 8 h. The plasma was separated and analysed for the presence of phosphonoformate by an HPLC method (Pettersson et al., 1989) . The rat plasma was also analysed for the presence of compound 6f by means of HPLC. An analytical column (ZORBAX SB-C8, 75×4.6 mm ID with 3.5 µM particles) was operated at 35°C with 35% acetonitrile in PBS, pH 5.8, as mobile phase at a flow rate of 1.2 ml/min and using electrochemical detection.
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Results
The neoglycolipid conjugates of foscarnet (6a-g), in which the carboxyphosphonyl substituent was attached to the 6-hydroxyl group, were synthesized as shown in Figure 2 . Thus the protected glycosyl donor as a mixture of anomeric acetates was reacted with the higher alkanol in the presence of trimethylsilyl triflate to give after deprotection the alkyl glycopyranoside (1a-d). In order to prepare the 6-Ocarboxyphosphonyl derivatives, the alkyl glycopyranosides were first 6-O-tritylated, then benzoylated to give after detritylation the alkyl 2,3,4-tri-O-benzoylglycopyranoside (4a-g). In order to introduce the carboxyphosphonyl substituent, a method for the synthesis of monoalkyl phosphonates (Sasse, 1963) , which has previously been used for the synthesis of foscarnet monoalkyl esters (Meier et al., 1998) , was employed. Reaction of the partially protected glycoside (4a-g) with 1.6 equivalents of ethoxycarbonylphosphonic dichloride gave in good yield after aqueous work-up the 6-O-ethoxycarbonylphosphonyl derivative (5a-g), which was deprotected by hydrolysis in dilute aqueous NaOH to afford the final product (6a-g). In order to prepare the 4-O-carboxyphosphonyl derivative (12) (Figure 3 ), dodecyl-β-D-glucopyranoside was converted to the 4,6-O-benzylidene derivative which was benzylated and subjected to reductive opening of the acetal group with sodium cyanoborohydride (Garegg & Hultberg, 1981) to afford dodecyl 2,3,6-tri-O-benzyl-β-D-glucopyranoside (9). This compound was then converted to the 4-Oethoxycarbonylphosphonyl derivative (10) as described above for the 6-O-ethoxycarbonylphosphonyl derivatives and deprotected in two steps to give the required compound 12.
The eight neoglycolipid conjugates of foscarnet were evaluated for antiviral activity in vitro in HL cells infected with HCMV or HSV-1 with foscarnet as reference compound. IC 50 values are given in Table 1 . For comparative purposes, Table 1 includes test data on the neoglycolipid 2f. The cytotoxicity of the test compounds in uninfected cells was assessed by measuring the capacity of mitochondrial enzymes to transform MTT tetrazolium salt into MTT formazan (Mossman, 1983) . The TC 50 values and selectivity indices (TC 50 /IC 50 ) for each virus are also given in Table 1 .
The antiviral activity of the neoglycolipid conjugates of foscarnet, in which the carboxyphosphonyl substituent was attached to the 6-hydroxyl group of the neoglycolipid and the lipid group consisted of 14 to 20 carbon atoms, was approximately 15 to 50 times that of foscarnet against HCMV and approximately 3.5 to 15 times that of foscarnet against HSV-1. The compounds showing the highest antiviral activity were trans-9-octadecen-1-yl 6-O-carboxyphosphonyl-α-D-glucopyranoside (6c), which was approximately 50 times more active than foscarnet against HCMV, and eicosyl 6-O-carboxyphosphonyl-β-D-galactopyranoside (6d), which was approximately 15 times more active than foscarnet against HSV-1. However, the dodecyl glycoside 6e and, in particular, its 4-O-carboxyphosphonyl analogue 12 with the β-anomeric configuration were less active. The neoglycolipid conjugates exhibited cytotoxic effects at TC 50 values that were 30 to 350 times higher than their IC 50 values against HCMV and 5 to 15 times higher than their IC 50 values against HSV-1. However, the neoglycolipid 2f showed a cytotoxic effect at a TC 50 value that was only three to four times its IC 50 value against HSV-1 and HCMV.
The formation of phosphonoformate could not be detected on incubation of compound 6f with rat liver or intestine homogenates. On oral administration of compound 6f, neither intact compound 6f nor phosphonoformate could be detected in rat plasma by HPLC.
Discussion
Although foscarnet is in clinical use for the treatment of HCMV retinitis and acyclovir-unresponsive HSV in AIDS patients, the clinical potential of the compound is limited as a result of its poor oral absorption and poor cell penetration (Wagstaff & Bryson, 1994) . Attempts have been made to improve oral absorption by formation of bioreversible prodrugs designed to release foscarnet following uptake from the gastrointestinal tract (Briggs et al., 1996 (Briggs et al., , 1997 Meier et al., 1998) , but this approach has not been particularly successful. However, lipid prodrugs of foscarnet such as 1-O-octadecyl-sn-glycero-3-phosphonoformate show enhanced antiviral activity as a result of their improved cell penetration followed by intracellular release of foscarnet (Hostetler et al., 1996) . The thioglycero analogue, 1-S-octadecyl-sn-thioglycero-3-phosphonoformate, shows similar antiviral activity to its glycero counterpart and has been found to be well absorbed orally in mice compared to phosphonoformate (Beadle et al., 1998) .
In the present study, it has been found that neoglycolipid conjugates of foscarnet show enhanced antiviral activity against HCMV and HSV-1 with good separation between antiviral activity (IC 50 ) and cytotoxicity (TC 50 ), the selectivity indices (TC 50 /IC 50 ) being at least five for HSV-1 and at least 30 for HCMV (Table 1) . Seven of the eight compounds tested were glucosides, compound 6d being a galactoside. Compounds in which the lipid group consists of 14 to 20 carbon atoms and with the carboxyphosphonyl substituent attached to the 6-hydroxyl group of the glycopyranose ring were particularly active, especially against HCMV. Attachment of the carboxyphosphonyl substituent to the 4-hydroxyl group of the glycopyranose ring instead of to the 6-hydroxyl group results in diminished antiviral activity since compound 12 is 4.5 times less active than compound 6e against HCMV. The anomeric configuration of the glycoside may have a marginal influence on the antiviral activity since compound 6g, which is a β-anomer, is somewhat less active than the corresponding α-anomer, compound 6f. The absence of the 6-O-carboxyphosphonyl substituent, as in compound 2f, results in lower antiviral activity and a low selectivity index.
Compounds 6c and 6d, which show the highest antiviral activity against HCMV and HSV-1, respectively, have been found in a separate study to be approximately 20 times more active against than foscarnet in HIV-1-infected cells and to show pronounced synergy against HIV-1 replication when combined with lamivudine (unpublished results).
The in vitro hydrolysis experiments with compound 6f using rat tissue homogenates indicate that the neoglycolipid conjugates of foscarnet do not liberate foscarnet under these conditions. The in vivo experiments with compound 6f in the rat show that it is not delivered by the oral route. This may be due to the high polarity of compound 6f as indicated by its distribution coefficient, logD octanol/water , which was -1.7 ( J Carlqvist, personal communication). Thus, less polar analogues or derivatives appear to be required for oral bioavailability.
The enhanced antiviral activity of the neoglycolipid conjugates of foscarnet, like that of the glycerolipid conjugates (Hostetler et al., 1996) , may well depend on their facilitated cellular uptake, followed by intracellular release of foscarnet. However, further investigations on the pharmacokinetics and the cellular transport and metabolism of the neoglycolipid conjugates of foscarnet are required in order to determine their usefulness as potential oral or parenteral drug targeting forms of foscarnet.
